Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
124.20    -5.80 (-4.46%)
Bid:
124.60
Ask:
125.00
Spread: 0.40 (0.321%)
Market Cap: £302.33m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Form 8.3 PURETECH HEALTH PLC

9 Apr 2025 15:00

RNS Number : 3674E
Barclays PLC
09 April 2025
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

PURETECH HEALTH PLC

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

08 Apr 2025

(f)

In addition to the company in 1(c) above, is the discloser making

NO

 

 

 

disclosures in respect of any other party to the offer?

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

1p ordinary

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

2,205,907

0.92%

2,517,260

1.05%

(2)

Cash-settled derivatives:

 

 

 

 

 

and/or controlled:

 

 

2,451,809

1.02%

2,087,421

0.87%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

4,657,716

1.94%

4,604,681

1.92%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

1p ordinary

Purchase

152,552

1.2300 GBP

1p ordinary

Purchase

93,847

1.1760 GBP

1p ordinary

Purchase

49,000

1.2071 GBP

1p ordinary

Purchase

41,800

1.2134 GBP

1p ordinary

Purchase

28,651

1.1823 GBP

1p ordinary

Purchase

28,186

1.2161 GBP

1p ordinary

Purchase

19,419

1.2157 GBP

1p ordinary

Purchase

18,866

1.2418 GBP

1p ordinary

Purchase

17,289

1.2142 GBP

1p ordinary

Purchase

11,128

1.2118 GBP

1p ordinary

Purchase

8,660

1.2486 GBP

1p ordinary

Purchase

8,362

1.2150 GBP

1p ordinary

Purchase

7,858

1.1826 GBP

1p ordinary

Purchase

5,000

1.2500 GBP

1p ordinary

Purchase

1,606

1.2359 GBP

1p ordinary

Purchase

519

1.2100 GBP

1p ordinary

Purchase

481

1.2520 GBP

1p ordinary

Purchase

378

1.2010 GBP

1p ordinary

Purchase

286

1.1860 GBP

1p ordinary

Purchase

242

1.2070 GBP

1p ordinary

Sale

319,914

1.2115 GBP

1p ordinary

Sale

179,673

1.2219 GBP

1p ordinary

Sale

134,381

1.2193 GBP

1p ordinary

Sale

77,849

1.2235 GBP

1p ordinary

Sale

76,662

1.2319 GBP

1p ordinary

Sale

40,542

1.2230 GBP

1p ordinary

Sale

38,965

1.2232 GBP

1p ordinary

Sale

25,463

1.1921 GBP

1p ordinary

Sale

22,552

1.2203 GBP

1p ordinary

Sale

17,757

1.2165 GBP

1p ordinary

Sale

12,310

1.2143 GBP

1p ordinary

Sale

4,114

1.2103 GBP

1p ordinary

Sale

3,991

1.2201 GBP

1p ordinary

Sale

2,549

1.2209 GBP

1p ordinary

Sale

1,780

1.2275 GBP

1p ordinary

Sale

1,457

1.2285 GBP

1p ordinary

Sale

1,160

1.2202 GBP

1p ordinary

Sale

991

1.2530 GBP

1p ordinary

Sale

865

1.2145 GBP

1p ordinary

Sale

759

1.2140 GBP

1p ordinary

Sale

382

1.1760 GBP

1p ordinary

Sale

378

1.2010 GBP

1p ordinary

Sale

270

1.2150 GBP

1p ordinary

Sale

242

1.2070 GBP

1p ordinary

Sale

179

1.2440 GBP

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

1p ordinary

SWAP

Increasing Long

42,790

1.1760 GBP

1p ordinary

SWAP

Increasing Long

59,391

1.1841 GBP

1p ordinary

SWAP

Increasing Long

25,463

1.1921 GBP

1p ordinary

SWAP

Increasing Long

2,241

1.1959 GBP

1p ordinary

SWAP

Increasing Long

9,453

1.2041 GBP

1p ordinary

SWAP

Increasing Long

134,381

1.2193 GBP

1p ordinary

SWAP

Increasing Long

10,046

1.2216 GBP

1p ordinary

SWAP

Increasing Long

179,673

1.2219 GBP

1p ordinary

SWAP

Increasing Long

1,873

1.2240 GBP

1p ordinary

SWAP

Increasing Long

4,305

1.2255 GBP

1p ordinary

SWAP

Increasing Long

181,777

1.2269 GBP

1p ordinary

SWAP

Increasing Long

3,485

1.2274 GBP

1p ordinary

SWAP

Increasing Long

27,074

1.2376 GBP

1p ordinary

SWAP

Increasing Long

7,498

1.3000 GBP

1p ordinary

SWAP

Decreasing Long

33,283

1.1760 GBP

1p ordinary

SWAP

Decreasing Long

180,074

1.2277 GBP

1p ordinary

CFD

Increasing Long

5,470

1.2015 GBP

1p ordinary

CFD

Increasing Long

5,648

1.2253 GBP

1p ordinary

CFD

Increasing Long

16,624

1.2296 GBP

1p ordinary

CFD

Decreasing Long

19,363

1.1760 GBP

1p ordinary

CFD

Decreasing Long

1,468

1.3001 GBP

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercising

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i) the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

09 Apr 2025

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETILMJTMTAMBRA
Date   Source Headline
29th May 20265:00 pmRNSHolding(s) in Company
27th May 20265:30 pmRNSHolding(s) in Company
22nd May 20265:00 pmRNSHolding(s) in Company
15th May 20267:00 amRNSCorrection - Holding(s) in Company
13th May 202612:00 pmRNS-RPRTC To Showcase Deupirfenidone at ATS Conference
8th May 20267:00 amRNSHolding(s) in Company
7th May 20266:27 pmRNSHolding(s) in Company
1st May 20267:00 amRNSPureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
29th Apr 20267:01 amRNSFinal Results
29th Apr 20267:00 amRNSPRTC Voluntarily Delists Nasdaq Depositary Shares
27th Apr 20266:09 pmRNSHolding(s) in Company
27th Apr 202612:05 pmRNS-RPRTC's Seaport Adds Neuropsychiatry Veteran to BOD
24th Apr 20265:58 pmRNSHolding(s) in Company
22nd Apr 202612:00 pmRNS-RPRTC's Gallop: Positive Ph1 Topline MDS & AML Data
16th Apr 20265:00 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSHolding(s) in Company
13th Apr 20267:05 amRNSNotice of Results
13th Apr 20267:00 amRNSPRTC's Seaport Files for Proposed Nasdaq IPO
1st Apr 20267:00 amRNSTotal Voting Rights
25th Mar 20266:00 pmRNS-RPRTC’s Seaport: GlyphAllo Paper Published
13th Mar 20264:35 pmRNSPDMR Notification RSU Vesting
2nd Mar 20267:00 amRNSTotal Voting Rights
25th Feb 20267:00 amRNS-RPRTC to Present at Leerink Healthcare Conference
19th Feb 20265:15 pmRNS-RPRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 202612:00 pmRNS-RPureTech to Present at the JP Morgan Conference
18th Dec 20257:00 amRNSPureTech Appoints Robert Lyne as CEO
10th Dec 20255:41 pmRNSResults of AGM on June 16, 2025 – Update Statement
10th Dec 20255:30 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RPRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
5th Dec 20256:00 pmRNS-RPRTC's Gallop: Positive Initial Topline AML Data
18th Nov 20255:30 pmRNSHolding(s) in Company
7th Nov 20256:18 pmRNSHolding(s) in Company
3rd Nov 20252:00 pmRNS-RPRTC: New LYT-200 AML Data + Update at ASH
22nd Oct 20257:00 amRNS-RPRTC: New IPF Data Show Benefit in Older Patients
17th Oct 20255:30 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSHolding(s) in Company
10th Oct 20255:59 pmRNSHolding(s) in Company
9th Oct 20256:10 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
29th Sep 20257:00 amRNS-RPRTC: New IPF Data Show Switch Patients Stabilized
24th Sep 20257:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Sep 20255:30 pmRNSHolding(s) in Company
19th Sep 20255:52 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNSHolding(s) in Company
11th Sep 202512:05 pmRNS-RPRTC's Seaport Advances 2nd Candidate Into Clinic
4th Sep 20255:30 pmRNSHolding(s) in Company
1st Sep 20257:00 amRNSTotal Voting Rights
28th Aug 20257:00 amRNSHalf-year Report
21st Aug 202512:00 pmRNS-RPureTech Showcases Differentiated IPF Strategy
18th Aug 20257:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.